https://scholars.lib.ntu.edu.tw/handle/123456789/551143
標題: | Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy | 作者: | CHEN-HUA LIU Liang C.-C. CHUN-JEN LIU TAI-CHUNG TSENG Lin C.-L. Yang S.-S. TUNG-HUNG SU SHIH-JER HSU JOU-WEI LIN Chen J.-H. PEI-JER CHEN DING-SHINN CHEN JIA-HORNG KAO |
公開日期: | 2012 | 出版社: | International Medical Press Ltd | 卷: | 17 | 期: | 3 | 起(迄)頁: | 477-484 | 來源出版物: | Antiviral Therapy | 摘要: | Background: Interleukin 28B (IL28B) single nucleotide polymorphism (SNP) genotypes and viral factors can predict sustained virological response (SVR) in HCV genotype-1 (HCV-1) patients receiving 48 weeks of pegylated interferon and ribavirin. Whether these factors would identify those patients who can benefit from a shorter duration of therapy remains unclear. Methods: Treatment-naive HCV-1 patients (n=662) receiving 24 or 48 weeks of combination therapy were enrolled. Baseline demographic data, HCV viral load, IL28B SNP genotypes (rs8099917), duration of therapy and rapid virological response (RVR) were evaluated to predict SVR. The SVR rates were further stratified by the independent factors and compared. Results: The IL28B rs8099917 TT genotype, low baseline viral load (HCV RNA?600,000 IU/ml), RVR and 48-week therapy independently predicted SVR. In RVR patients with the IL28B rs8099917 TT genotype, the SVR rate of 24-week therapy was comparable to 48-week therapy (95% versus 99%; P=0.21) at low baseline viral load, but was inferior to 48-week therapy (70% versus 97%; P<0.001) at high baseline viral load. In non-RVR patients, the SVR rate of 24-week therapy was inferior to 48-week therapy for those with the IL28B rs8099917 TT genotype but high baseline viral load (23% versus 62%; P<0.001), and those with the IL28B rs8099917 GT/GG genotype but low baseline viral load (0% versus 33%; P=0.02). Conclusions: HCV-1 patients simultaneously bearing the IL28B rs8099917 TT genotype, low baseline viral load and RVR can benefit from a shorter duration of combination therapy. ?2012 International Medical Press. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984586976&doi=10.3851%2fIMP2026&partnerID=40&md5=cbc647e58cbf89a2fc7a1ead4597ab91 https://scholars.lib.ntu.edu.tw/handle/123456789/551143 |
ISSN: | 1359-6535 | DOI: | 10.3851/IMP2026 | SDG/關鍵字: | interleukin 28B; peginterferon alpha2a; ribavirin; adult; article; female; gene; genotype; hepatitis C; Hepatitis C virus; human; IL28B gene; major clinical study; male; nonhuman; priority journal; rapid virological response; single nucleotide polymorphism; sustained virological response; treatment duration; treatment response; viral phenomena and functions; virus load |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。